Health
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial – GlobeNewswire
NEW YORK and MAINZ, GERMANY, Sept. 12, 2020 (GLOBE NEWSWIRE) — NEW YORK and MAINZ, GERMANY, September 12 — Pfizer Inc. (NYSE: PFE) and BioNTech…
NEW YORK and MAINZ, GERMANY, Sept. 12, 2020 (GLOBE NEWSWIRE) —
NEW YORKand MAINZ, GERMANY, September 12 Pfizer Inc.
(NYSE: PFE) and BioNTech SE
(NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
Enrollment in the trial has been proceeding as planned an…
-
Business15 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
General24 hours agoLiberals dump NSW candidate who said women should not serve in ADF combat
-
Business11 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts